Video from ASH 2021: Advances in treating myeloid disorders

Dec 14, 2021
2021 12 15 17 51 2318 Sekeres Mikkael

Major advances in treating patients with myeloid disorders were presented at the American Society of Hematology (ASH) 2021 meeting in Atlanta. LabPulse.com spoke with Dr. Mikkael Sekeres about some of these exciting developments.

Sekeres is chief of the division of hematology at the Sylvester Comprehensive Cancer Center in Miami. He also serves as ASH's communications director. Sekeres' research interests are in leukemias, myelodysplastic syndromes, and myeloid malignancies.

Click on the video below to hear his thoughts.


Latest in Leukemia
Blood Test Samples Lab Social
Bio-Techne receives IVDR certification for chronic myeloid leukemia monitoring test
March 22, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Leukemia Aml Social
Blood test identifies acute myeloid leukemia patients at greater risk of relapse
March 8, 2023
2021 06 09 22 54 4801 Computer Doctor Scientist 400
Scopio digital platform enables bone marrow aspirate imaging
September 7, 2022
Related Stories
2019 08 02 16 42 5947 Lab Blood Man 400
Hematology
ASH-ASPHO offers guidance on pediatric hematology tests
2021 12 10 19 28 1244 Ash 2021 Sign 400
Hematology
Video from ASH 2021: Sickle-cell patients, activists tell their stories
2021 12 10 19 28 1244 Ash 2021 Sign 400
Gene expression
Video from ASH 2021: Gene therapy 2.0: The latest in gene editing
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Leukemia
Bio-Techne receives IVDR certification for chronic myeloid leukemia monitoring test
By LabPulse.com staff writers
Bio-Techne has announced that Asuragen, part of its molecular diagnostics division, has completed class C certification under the new European Union IVDR for its QuantideX qPCR BCR-ABL IS kit for monitoring chronic myeloid leukemia.
March 22, 2024
Blood Test Samples Lab Social
ThinkCyte, Sysmex, Juntendo University partner on chronic myelogenous leukemia research
By LabPulse.com staff writers
The collaborative team has been developing approaches to characterize CML-specific morphological differences between blood cancer cells and normal white blood cells using Ghost Cytometry.
April 18, 2023
Artificial Intelligence Ai Abstract Social
Blood test identifies acute myeloid leukemia patients at greater risk of relapse
By Elissa Wolfson
According to a study, patients in remission from acute myeloid leukemia who have residual detectable mutations have higher relapse rates after bone marrow transplants.
March 8, 2023
Leukemia Aml Social
Scopio digital platform enables bone marrow aspirate imaging
By LabPulse.com staff writers
Bone marrow aspirates are normally conducted manually, using microscopic analysis of cells to diagnose cancers such as leukemia and multiple myeloma.
September 7, 2022
2021 06 09 22 54 4801 Computer Doctor Scientist 400
Thermo Fisher develops NGS assay for myeloid MRD research
By LabPulse.com staff writers
Among the first NGS-based tests to support both DNA and RNA input, the research-use-only Ion Torrent Oncomine Myeloid MRD Assay provides an MRD assessment from blood and bone marrow samples, Thermo Fisher said.
August 3, 2022
2020 01 14 22 12 7635 Dna Sequencing2 400
SeekIn receives CE Mark for karyotyping kit
By LabPulse.com staff writers
Designed to show copy number alteration patterns in leukemia patients based on shallow whole-genome sequencing, the test can help hematologists make diagnoses and prognostic decisions based on European Leukemia Net, Revised International Prognostic Scoring System, or Revised International Staging System guidelines, according to the vendor.
April 6, 2022
2019 05 21 23 51 7032 Blood Cell Clot 400
Genialis partners with OncXerna to improve targeted therapy
By LabPulse.com staff writers
Genialis' ResponderID will use OncXerna's XernaTME (tumor microenvironment) panel to incorporate the pancancer tumor microenvironment classifier to investigate potentially hundreds of new use cases for personalized therapeutic selection.
April 5, 2022
2019 04 22 23 41 4967 Cancer Cell Target2 400
Sysmex develops new leukemia liquid biopsy test
By LabPulse.com staff writers
The new test, AML-MRD-SEQ, uses a targeted next generation sequencing (NGS) panel, which covers 68 regions across 20 genes, including established MRD markers such as NPM1.
October 19, 2021
2019 05 21 17 23 2291 Liquid Biopsy Labs Test Tubes 400
Third Opinion touts AI disease detection results
By LabPulse.com staff writers
The patented software achieved a median accuracy of 83.8% for classifying 70 types of blood cells and detected 35 out of 70 specific types of blood cells, the company said. It had a 95% accuracy rate in detection of the 35 most common cells for different types of leukemia.
July 1, 2021
2021 04 27 15 25 5437 Pathology Digital Workstation Microscope 400
NuProbe introduces pancancer liquid biopsy test
By LabPulse.com staff writers
Driven by the company's proprietary blocker displacement amplification technology, the test can detect and quantitate over 6,500 mutations and indels in 61 clinically relevant genes, according to the company. The high sensitivity possible with the product is suitable for detection of minimal residual disease in acute myeloid leukemia and other diseases, NuProbe said in a statement.
February 21, 2021
2020 01 16 22 39 3973 Dna Sequencing Genome 400
Thermo Fisher debuts hematology/oncology assays
By LabPulse.com staff writers
The Oncomine Myeloid Assay Gx is designed for Thermo Fisher's Ion Torrent Genexus system. The assay also enables researchers to profile 40 DNA targets and 29 fusion driver genes; this enables the detection of more than 600 fusion isotypes for identifying biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia, and myelodysplastic syndrome.
August 18, 2020
2017 09 14 23 05 1167 Cancer Cell 400
Thermo Fisher debuts infectious disease quality controls
By LabPulse.com staff writers
The Thermo Scientific Mas Omni Infectious positive and negative quality controls are third-party, independent external controls used to assess the performance of serological assays for HIV types 1 and 2, hepatitis B and C, syphilis, and human T-cell leukemia virus types 1 and 2. Monitoring the assays' performance can streamline operations and may reduce spending without sacrificing quality, according to the company.
June 30, 2020
2020 07 01 16 59 5154 Thermo Fisher Qualitycontrol 400
Page 1 of 2
Next Page